Patents by Inventor Peter J. Schatz
Peter J. Schatz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6716811Abstract: Novel compounds are provided that bind to G-CSFR. The novel compounds have a peptide chain approximately 6 to 40 amino acids in length that binds to G-CSFR. The compounds are useful as probes for affinity screening. In addition, the compounds have demonstrated agonist or antagonist activity for the G-CSFR, and are therefore useful in treatment of diseases including patients who suffer from a low white blood cell titer. Pharmaceutical compositions and methods of use are provided as well.Type: GrantFiled: July 20, 2000Date of Patent: April 6, 2004Assignee: Affymax, Inc.Inventors: Steven E. Cwirla, Palani Balu, David J. Duffin, Sunila Piplani, Barbara McEowen Merrill, Peter J. Schatz
-
Publication number: 20030158116Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: ApplicationFiled: February 27, 2002Publication date: August 21, 2003Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
-
Patent number: 6506362Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: GrantFiled: April 10, 2001Date of Patent: January 14, 2003Assignee: Glaxo Group LimitedInventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
-
Patent number: 6465430Abstract: Receptors are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: GrantFiled: April 13, 2000Date of Patent: October 15, 2002Assignee: SmithKline Beecham CorporationInventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
-
Patent number: 6410245Abstract: The invention provides methods for identifying agents that are ligands for nuclear receptors. The methods include conducting multiplexed assays utilizing positive hybrid systems, reverse hybrid systems, direct interaction assays and other assays to screen for ligands having activity with a receptor of interest. The methods can be performed in various multiplexing formats to produce a profile that can be used to categorize a test ligand relative to known agonists and antagonists.Type: GrantFiled: April 1, 1998Date of Patent: June 25, 2002Assignee: Affymax, Inc.Inventors: Jeffrey P. Northrop, Charles P. Hart, Peter J. Schatz
-
Patent number: 6309842Abstract: The invention provides methods for screening libraries of complexes for compounds having a desired property, especially, the capacity to agonize, bind to, or antagonize a cellular receptor. The complexes in such libraries comprise a compound under test, a tag recording at least one step in synthesis of the compound, and a tether susceptible to modification by a reporter molecule. Modification of the tether is used to signify that a complex contains a compound having a desired property. The tag can be decoded to reveal at least one step in the synthesis of such a compound.Type: GrantFiled: November 24, 1997Date of Patent: October 30, 2001Assignee: Glaxo Wellcome Inc.Inventors: William J. Dower, Christian M. Gates, Gregory L. Heinkel, Guy Lalonde, Larry C. Mattheakis, Christopher J. Paddon, Peter J. Schatz
-
Patent number: 6265552Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.Type: GrantFiled: February 24, 2000Date of Patent: July 24, 2001Assignee: Affymax Technologies N.V.Inventor: Peter J. Schatz
-
Patent number: 6251864Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: GrantFiled: March 1, 2000Date of Patent: June 26, 2001Assignee: Glaxo Group LimitedInventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
-
Patent number: 6156511Abstract: A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also encode a binding site for the DNA. binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.Type: GrantFiled: January 21, 1998Date of Patent: December 5, 2000Assignee: Affymax Technologies N.V.Inventors: Peter J. Schatz, Millard G. Cull, Jeff F. Miller, Willem Peter Christiaan Stemmer, Christian M. Gates
-
Patent number: 6121238Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: GrantFiled: February 3, 1999Date of Patent: September 19, 2000Assignee: Glaxo Wellcome Inc.Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
-
Patent number: 6083913Abstract: Receptors are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: GrantFiled: December 4, 1997Date of Patent: July 4, 2000Assignee: Glaxo Wellcome Inc.Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
-
Patent number: 5958703Abstract: The invention provides methods for screening libraries of complexes for compounds having a desired property, especially, the capacity to agonize, bind to, or antagonize a cellular receptor. The complexes in such libraries comprise a compound under test, a tag recording at least one step in synthesis of the compound, and a tether susceptible to modification by a reporter molecule. Modification of the tether is used to signify that a complex contains a compound having a desired property. The tag can be decoded to reveal at least one step in the synthesis of such a compound.Type: GrantFiled: December 3, 1996Date of Patent: September 28, 1999Assignee: Glaxo Group LimitedInventors: William J. Dower, Gregory L. Heinkel, Larry Mattheakis, Peter J. Schatz
-
Patent number: 5932433Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.Type: GrantFiled: October 28, 1997Date of Patent: August 3, 1999Assignee: Affymax Technologies N.V.Inventor: Peter J. Schatz
-
Patent number: 5874239Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.Type: GrantFiled: July 15, 1996Date of Patent: February 23, 1999Assignee: Affymax Technologies N.V.Inventor: Peter J. Schatz
-
Patent number: 5869451Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: GrantFiled: December 11, 1996Date of Patent: February 9, 1999Assignee: Glaxo Group LimitedInventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randoph B. DePrince, Surekha Podduturi, Qun Yin
-
Patent number: 5733731Abstract: A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also encode a binding site for the DNA binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.Type: GrantFiled: October 26, 1995Date of Patent: March 31, 1998Assignee: Affymax Technologies N.V.Inventors: Peter J. Schatz, Millard G. Cull, Jeff F. Miller, Willem Peter Christiaan Stemmer, Christian M. Gates
-
Patent number: 5723584Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.Type: GrantFiled: February 3, 1995Date of Patent: March 3, 1998Assignee: Affymax Technologies N.V.Inventor: Peter J. Schatz
-
Patent number: 5683983Abstract: Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: GrantFiled: June 7, 1995Date of Patent: November 4, 1997Assignee: Glaxo Group LimitedInventors: Ronald W. Barrett, Bruce P. England, Peter J. Schatz, Derek Sloan, Min-Jia Chen
-
Patent number: 5677280Abstract: Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: GrantFiled: June 7, 1995Date of Patent: October 14, 1997Assignee: Glaxo Group LimitedInventors: Ronald W. Barrett, Bruce P. England, Peter J. Schatz, Derek Sloan, Min-Jia Chen
-
Patent number: 5668110Abstract: Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.Type: GrantFiled: June 7, 1995Date of Patent: September 16, 1997Assignee: Affymax Technologies N.V.Inventors: Ronald W. Barrett, Bruce P. England, Peter J. Schatz, Derek Sloan, Min-Jia Chen